LL-37

LL-37 is unusual in this library, and in a direction worth naming up front. Most compounds here are short of human evidence. This one has three randomised placebo-controlled trials, which is more than almost anything else in the collection.

The catch is what those trials were and what they found. All three were topical, on chronic leg or foot ulcers, in clinical settings. The largest, a phase IIb with 149 patients randomised, found no significant improvement over placebo in the full study population. So the evidence here is real, and it points away from the compound rather than toward it. LL-37 is also a genuine part of human biology rather than a designer molecule, which makes the distinction between what the body does with it and what happens when it is given from outside the central question.

LL-37 is a chain of thirty-seven amino acids released from a precursor protein called hCAP18. It is the only cathelicidin humans produce, and it turns up wherever the body meets the outside world: in neutrophils, in skin, in the epithelial linings of the airway and gut.

That matters for reading claims about it. This is not a compound somebody designed and then looked for a use for. It is a working part of innate immune defence with a well-described role, and the marketing borrows credibility from that role. The question a reader should hold is not whether LL-37 does anything in the body, because it clearly does. It is whether giving more of it from outside reproduces any of that, and the trials are where the answer lives.

Where the Biology Gets Interesting

Antimicrobial peptides attracted decades of interest for a specific reason. Most antibiotics hit a particular molecular target, and bacteria evolve around particular targets. A cationic peptide that disrupts the microbial membrane itself is a blunter instrument and, in principle, a harder one to develop resistance against.

LL-37 does more than that. It draws immune cells toward a site, neutralises bacterial lipopolysaccharide, and appears strongly at the edge of an acute injury early in repair while being only weakly present in chronic ones. That last observation is the whole reason the ulcer trials happened: if a stalled ulcer is short of the peptide a healing one has, supplying it topically is a reasonable thing to test. It was tested. The results are below.

The Mechanism, Without Overstating It

The proposed action is direct membrane disruption of bacteria, fungi and some viruses, alongside immune signalling that recruits cells and dampens the response to bacterial endotoxin. Both halves are well described for the endogenous peptide.

The same properties create two limits that have shaped everything since, and both are measured rather than assumed. A membrane-disrupting peptide does not perfectly distinguish a microbial membrane from a host one, and laboratory work reports toxicity toward mammalian cells at higher concentrations. Separately, its antimicrobial activity is inhibited by serum.

Read together, those two findings explain the shape of the entire clinical literature. Serum is precisely what a systemic route exposes a peptide to, so the environment that would carry LL-37 around the body is also the environment where its antimicrobial action is weakest. That is why every human trial is topical, and it is a pharmacological reason rather than a historical accident.

The overreach on this compound is unusual because it runs through real evidence rather than around an absence.

The first error is quoting the small trial and not the large one. The 34-patient study is encouraging and is the one that circulates. The 149-patient study is the one designed to answer the question, and it came back null. When a small positive result does not survive a larger trial, the larger trial is the finding.

The second is treating a post hoc subgroup as a result. The larger-ulcer subgroup was identified after the fact, in a study whose main comparison had already failed, and the authors are explicit that it needs a further powered study. It is a hypothesis, not an outcome.

The third is carrying topical findings to other routes. On most compounds that would be caution. Here it is a specific pharmacological objection: activity is inhibited by serum, and toxicity toward mammalian cells is reported at higher concentrations.

The fourth is mistaking a surrogate for an outcome. In the diabetic foot ulcer study the granulation index moved and wound area reduction did not. Those are different claims and only one of them was demonstrated.

Tolerability in the topical trials was good, and that is worth stating plainly because it is a real finding rather than an absence. Across the venous leg ulcer studies the peptide was reported as well tolerated at both strengths tested, under clinical supervision, on a defined area of skin, over defined periods.

No human safety data exists for any other route. Nobody has published a trial of systemic LL-37 in people, so there is nothing to report about tolerance, adverse effects, or what repeated exposure does. That gap sits alongside the laboratory finding of toxicity toward mammalian cells at higher concentrations, which is the kind of result that makes the missing data matter rather than being merely unexamined.

There is no approved LL-37 product anywhere, so material sold outside a research setting carries the usual identity and purity questions with nothing to compare it against. On anti-doping, LL-37 is not named on the 2026 Prohibited List, which is not permission: S0 prohibits at all times any substance with no current approval by any regulator for human therapeutic use, and LL-37 holds none. It sits on neither FDA 503A list today, but not because it was never considered: FDA reviewed it as “Cathelicidin LL-37” and its nomination was withdrawn in April 2026 by the nominator, not resolved by the agency. The concerns FDA published are more specific than for most of these compounds, citing nonclinical findings that suggest detrimental effects on male reproduction and that the compound can be protumorigenic in some tissues. FDA has said it intends to consult its advisory committee on cathelicidin LL-37 before the end of February 2027.

Read honestly, this entry supports a narrow and specific set of statements. LL-37 is a real human antimicrobial peptide with a described role in innate defence. Given topically on chronic leg and foot ulcers under clinical supervision, it has been well tolerated, it improved a tissue-formation measure in one small study, it showed a concentration-dependent signal in another, and it did not outperform placebo in the largest and best-designed trial of the three.

Nothing in that supports the reasons the compound is actually bought. There is no human evidence about immunity, chronic infection, gut health or performance, because no trial has looked. The honest position is that this is a well-studied molecule whose studies were about a different question and largely did not succeed at it.

Not an unstudied compound, and that cuts both ways. Three randomised placebo-controlled trials exist, which is more than almost anything else in this library, and the largest of them found no significant improvement over placebo.

Not effective in its largest trial. The phase IIb with 149 patients randomised did not identify any significant improvement in healing versus placebo across the full study population, and the larger-ulcer subgroup that did improve was a post hoc analysis the authors say needs replicating.

Not studied by any route other than topical. Every human trial applied it to the surface of a chronic ulcer, and laboratory work reports that serum inhibits its antimicrobial activity, which is an argument against the systemic route rather than a gap in the record.

Not evidence for immunity, gut health or infection resistance. No trial of this peptide has examined any of them, and the credibility of the ulcer studies does not transfer to questions they never asked.

Not a protocol or personal-use guide. This page describes what a small body of clinical research measured and gives no administration guidance of any kind.

LL-37 is the most rigorously studied compound in this expansion set and one of the least supportable, which is not a contradiction. Good evidence can return a negative answer, and that is what happened here: a promising first trial, a properly powered second trial that did not confirm it, and a laboratory literature that had already explained why the systemic route was unlikely to work.

We cover it because the pattern is worth recognising anywhere it appears. A compound with real trials behind it can still be sold on a claim those trials never tested, and a small positive study will keep circulating long after a larger one has answered the question. On the evidence available, this is a real human peptide with genuine clinical research, none of it about the reasons people buy it.